PreciseDx said it plans to use the investment to advance its AI for breast cancer diagnostics and risk assessment. The startup, which has brought in $31.5 million to date, has also started collaborating with Los Angeles-based UCLA Health, Coral Gables, Fla.-based Baptist Health, and Dallas-based Baylor Scott & White Health.
“Our team continues to advance breast cancer diagnostics by delivering faster, more accurate data, in a cost-efficient method,” said Eric Converse, founding board member of PreciseDx, in an Aug. 21 statement. “This allows clinical care teams to make better informed clinical decisions resulting in improved patient outcomes.”
The funding round was led by biotech investor Eventide Asset Management and also included laboratory giants Labcorp and Quest Diagnostics.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
